A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Pf 06649751 Co-administered With Trimethobenzamide Hydrochloride In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2015
Price : $35 *
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 13 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record..
- 07 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.